IBDEI0AK ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4970,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4970,1,4,0)
 ;;=4^414.3
 ;;^UTILITY(U,$J,358.3,4970,1,5,0)
 ;;=5^CAD d/t Lipid Rich Plaque
 ;;^UTILITY(U,$J,358.3,4970,2)
 ;;=^336601
 ;;^UTILITY(U,$J,358.3,4971,0)
 ;;=414.4^^41^478^16
 ;;^UTILITY(U,$J,358.3,4971,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4971,1,4,0)
 ;;=4^414.4
 ;;^UTILITY(U,$J,358.3,4971,1,5,0)
 ;;=5^CAD d/t Calc Coronary Lesion
 ;;^UTILITY(U,$J,358.3,4971,2)
 ;;=^340518
 ;;^UTILITY(U,$J,358.3,4972,0)
 ;;=425.11^^41^478^60
 ;;^UTILITY(U,$J,358.3,4972,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4972,1,4,0)
 ;;=4^425.11
 ;;^UTILITY(U,$J,358.3,4972,1,5,0)
 ;;=5^Hypertrophic Subaortic Stenosis
 ;;^UTILITY(U,$J,358.3,4972,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,4973,0)
 ;;=425.18^^41^478^59
 ;;^UTILITY(U,$J,358.3,4973,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4973,1,4,0)
 ;;=4^425.18
 ;;^UTILITY(U,$J,358.3,4973,1,5,0)
 ;;=5^Hypertrophic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,4973,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,4974,0)
 ;;=V12.55^^41^478^54
 ;;^UTILITY(U,$J,358.3,4974,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4974,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,4974,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,4974,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,4975,0)
 ;;=454.9^^41^478^84
 ;;^UTILITY(U,$J,358.3,4975,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4975,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,4975,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,4975,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,4976,0)
 ;;=271.3^^41^479^11
 ;;^UTILITY(U,$J,358.3,4976,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4976,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,4976,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,4976,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,4977,0)
 ;;=611.1^^41^479^16
 ;;^UTILITY(U,$J,358.3,4977,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4977,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,4977,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,4977,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,4978,0)
 ;;=704.1^^41^479^17
 ;;^UTILITY(U,$J,358.3,4978,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4978,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,4978,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,4978,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,4979,0)
 ;;=251.2^^41^479^30
 ;;^UTILITY(U,$J,358.3,4979,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4979,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,4979,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,4979,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,4980,0)
 ;;=253.2^^41^479^34
 ;;^UTILITY(U,$J,358.3,4980,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4980,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,4980,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,4980,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,4981,0)
 ;;=733.00^^41^479^43
 ;;^UTILITY(U,$J,358.3,4981,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4981,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,4981,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,4981,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,4982,0)
 ;;=278.00^^41^479^40
 ;;^UTILITY(U,$J,358.3,4982,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4982,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,4982,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,4982,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,4983,0)
 ;;=278.01^^41^479^39
 ;;^UTILITY(U,$J,358.3,4983,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4983,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,4983,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,4983,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,4984,0)
 ;;=250.80^^41^479^10
 ;;^UTILITY(U,$J,358.3,4984,1,0)
 ;;=^358.31IA^5^2
